🏛️ Verified NIH Record • Updated 2026-07-30
Study for AZD4360 in Participants With Advanced Solid Tumours (NCT06921928)
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: AstraZeneca
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Who can join: Review the eligibility criteria below.
Location: Research Site — Santa Monica, California
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Research Site — Santa Monica, California
- Research Site — Providence, Rhode Island
- Research Site — Houston, Texas
- Research Site — Beijing,
- Research Site — Chengdu,
- Research Site — Shanghai,
- Research Site — Wuhan,
- Research Site — Dresden,
- Research Site — Frankfurt,
- Research Site — Chūōku,
- Research Site — Kashiwa,
- Research Site — Kōtoku,
- Research Site — Glasgow,
- Research Site — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastric Cancer
- A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Scottsdale, Arizona
- Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer — Los Angeles, California
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) — Baltimore, Maryland
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer — Baltimore, Maryland
- Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma — Tampa, Florida
Explore by condition: All Gastric Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.